STAT+: Novo Nordisk enlists two Flagship biotechs to develop obesity, MASH drugs
Novo Nordisk may already have one blockbuster obesity drug in its portfolio, but the Danish drugmaker has actively begun searching out others, including through a new partnership announced Thursday.
Novo Nordisk will work with Omega Therapeutics, a startup founded by venture creation firm Flagship Pioneering, to develop a genetic editing treatment for obesity. The pharmaceutical company said Thursday that it has also signed a deal with Flagship-founded startup Cellarity to develop a new medicine for the fatty liver disease MASH, formerly known as NASH.
These are the first two deals announced under a collaboration agreement Flagship and Novo Nordisk struck in 2022.
